At Patheon, we deliver enhanced simplicity, speed, and quality to clients across the pharmaceutical and biotechnology sectors. As a leading global provider of pharmaceutical development and manufacturing services, we provide a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle.
Type
Subsidiary
HQ
Durham, US
Founded
1974
Patheon was founded in 1974 and is headquartered in Durham, US
Report incorrect company information

Patheon Office Locations

Patheon has an office in Durham
Durham, US (HQ)
300 4815 Emperor Blvd
Show all (1)
Report incorrect company information

Patheon Financials and Metrics

Summary Metrics

Founding Date

1974
Patheon is a subsidiary of Thermo Fisher Scientific

Patheon Financials

Patheon's revenue was reported to be $1.02 b in FY, 2013
USDFY, 2013

Revenue

1 b

Cost of goods sold

774 m

Gross profit

249.1 m

Gross profit Margin, %

24%
USDFY, 2013

Cash

61.6 m

Accounts Receivable

191.3 m

Inventories

137.8 m

Current Assets

415.7 m
USDFY, 2013

Depreciation and Amortization

48.4 m

Cash From Operating Activities

13 m
Show all financial metrics
Report incorrect company information

Patheon News and Updates

Thermo Fisher spotlights its problem-solvers in campaign aimed at pharma clients

​​​​​​​Thermo Fisher is showing its real face to pharma clients. Make that faces—those of its employees and the patients they help. In its new campaign, Thermo Fisher Scientific Pharma Services is looking to personalize its end-to-end drug development and delivery services for pharma companies.

Empty Capsules Market to Surpass US$ 2.79 Billion Threshold by 2025 Globally

Empty capsules market to surpass US$ 2.79 billion threshold by 2025 globally, with development of capsules integrated with advanced technologies such as extended release Posted via Industry Today. Follow us on Twitter @IndustryToday

Pharmaceutical Solid Dosage Contract Manufacturing Market to witness steady increase by 2024

The major factors that are driving the pharmaceutical solid dosage contract manufacturing market include lower and more flexible manufacturing, reduced net costs, streamlined development, and availability of the higher quality product. Posted via Industry Today. Follow us on Twitter @IndustryToday

Pharmaceutical Solid Dosage Contract Manufacturing Market: Industry Latest Trends & Global Outlook 2016-2024

The major factors that are driving the pharmaceutical solid dosage contract manufacturing market include lower and more flexible manufacturing, reduced net costs, streamlined development, and availability of the higher quality product. Posted via Industry Today. Follow us on Twitter @IndustryToday

Vicarius Pharma lands $21.8 mln

Switzerland-based Vicarius Pharma AG, which provides U.S.-based biopharmaceutical companies a "novel approach" to commercializing assets in European markets, has raised $21.8 million in funding. James Mullen, CEO of Patheon and former CEO of Biogen, was the lead investor.
Show more
Report incorrect company information